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ABSTRACT 
Pharmacological evaluation of antidiarrhoeal and antidiabetic activities of Syzygium 
cordatum Hochst.exC.Krauss. 
 
M.DELIWE 
M.Pharm. Pharmaceutical Sciences thesis: School of Pharmacy, University of the Western 
Cape 
Syzygium cordatum is a medicinal plant indigenous to South Africa and Mozambique, 
commonly used to treat stomach aches, diabetes, respiratory problems and tuberculosis. In 
spite of the folklore use, adequate scientific data to credit its widespread traditional use is 
lacking. 
The objectives of this study were: to evaluate and validate scientifically the successful 
therapeutic claims by traditional medicine practitioners that Syzygium cordatum is effective 
in treating diarrhoea and diabetes; to determine the effects of the plant extract on 
gastrointestinal transit of a charcoal meal in mice; to determine the effects on castor oil-
induced intestinal fluid accumulation; to determine the safety profile of the plant by carrying 
out acute toxicology study and  to carry out preliminary screening of the active compounds 
present in the plant using standard phytochemical analytical procedures. 
The aqueous leaf extract of Syzygium cordatum (3.125 -50mg/kg, p.o) significantly reduced 
the faecal output caused by castor oil (0.7ml). All the doses used, reduced faecal output from 
100% produced by castor oil to between 40 and 61%. S.cordatum (6.25 – 50mg/kg, p.o) 
significantly and in a dose dependent manner, delayed the onset of castor oil-induced 
diarrhoea. Doses 3.25 – 50mg/kg, p.o siginicantly reduced castor oil-induced diarrhoeal 
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episodes but did not significantly alter the number of animals exhibiting diarrhoea. 
Loperamide (20mg/kg, p.o) significantly reduced the faecal output  from 100% produced by 
castor oil to 8.7%. Loperamide profoundly delayed the onset of diarrhoea, reduced the 
incidence of castor oil-induced diarrhoea by protecting 83% of animal and reduced the 
number of castor oil-induced diarrhoeal episodes by 96%. 
The aqueous leaf extract of Syzygium cordatum inhibited the propulsion of the charcoal meal 
by 21.25 – 50.93% and loperamide reduced the propulsion of the charcoal meal by 79.06%. 
The aqueous leaf extract reduced the fluid accumulation caused by castor oil (1.5ml) by 41.55 
– 59.15% and loperamide (20mg/kg, p.o) reduced the castor oil (1.5ml)- induced 
gastrointestinal fluid accumulation by 52.82%. 
Syzygium cordatum (12.5 – 50mg/k, p.o) significantly reduced the blood glucose 
concentration of normal fasted rats by 28.60 – 32.79% and chlorpropamide (250mg/kg, p.o) 
significantly reduced the blood glucose concentration of normal fasted rats by 43.26%. 
Syzygium cordatum (6.25 – 50mg/kg, p.o) significantly reduced the blood glucose 
concentration of streptozotocin-induced diabetic rats with a maximal percentage reduction of 
35.54% and chlorpropamide (250mg/kg, p.o) profoundly reduced the blood glucose 
concentration of streptozotocin-induced diabetic rats with a maximal reduction of 93.42%. 
The phytochemical studies revealed the presence of tannins, saponins, alkaloids, flavonoids, 
triterpenesteroids  and reducing sugars in the aqueous extract of Syzygium cordatum. 
The aqueous leaf extract of Syzygium cordatum extract was found to be non-toxic in mice via 
the oral route with a maximum LD50 to be above 4000 mg/kg. 
 In conclusion, the results showed that the aqueous leaf extract of Syzygium cordatum 
possesses both antdiarrhoeal and antidiabetic activities 
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CHAPTER 1 
INTRODUCTION 
 Plants have, for generations, been a source of various kinds of remedies and been used for 
medicinal purpose to cure all kinds of ailments and will continue to provide remedies for 
these ailments, especially in rural areas in developing countries in the African continent (Watt 
and Breyer-Brandwijk, 1962; Van Wyk et al., 1997). 
It is estimated that around 70 000 plants species, from lichens to towering trees, have been 
used at one time or another for medicinal purposes. Medicinal plants or herbs are providing 
the starting material for the isolation or synthesis of conventional drugs. Herbs are becoming 
popular throughout the developed world, as people strive to stay healthy in the face of 
chronic stress and pollution, and to treat illness with medicines that work in concert with the 
body’s own defenses (Das Prajapati et al., 2003). 
According to Das Prajapati et al. (2003), medicinal plants have curative properties due to the 
presence of various complex chemical structures of different composition, which are found as 
secondary plant metabolites in one or more parts of the plant. Plant metabolites are grouped 
according to the composition as alkaloids, glycosides, corticosteroids, essential oils and so 
on. 
South Africa has a rich floral biodiversity with an estimated 30 000 species of higher plants, 
with 3000 of these plants used for medicinal purposes (Van Wyk et al., 1997; Light et al., 
2005 ). This rich cultural diversity in the country greatly, also, contributes to the blending of 
the cultures and is reflected in the systems of medicines practiced (Van Wyk et al., 
1997).Approximately, three million South Africans in both urban and rural areas are reliant  
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 on traditional medicine exclusively or in combination with western medicine (Van Wyk et 
al., 1997; Amabeoku et al., 1998; Jager et al., 2003; Light et al., 2005; Govender et al., 2006). 
Most traditional remedies in South Africa are prepared in unhygienic settings by herbalist or 
traditional healers therefore microbial contamination is likely to occur at any stage during 
preparation, handling and storage of the herbal product hence affecting the quality of the final 
product. Since South African lack stringent regulatory authority for herbal products therefore, 
basic research on herbal medicine should be geared towards toxicity and efficacy and 
authenticate the successful therapeutic claims as asserted by traditional healers, respectively 
(Ernst 2002; Govender at al., 2006). 
According to WHO (2008), traditional medicines are adopted in different cultures and 
regions without parallel advance of international standards and methods of evaluation. Not 
many countries have national policies and, regulating traditional medicine products, practices 
and practitioners is difficult due to variations in definitions and categorization of traditional 
medicine therapies. A single herbal product can either be defined as food, dietary supplement 
or a herbal medicine depending on the country. Scientific evidence from tests done to 
evaluate safety and effectiveness of traditional medicine products is limited (WHO, 2008).   
This, therefore, necessitates comprehensive research on traditional medicine products vis-à-
vis plant medicines including pharmacological evaluation to verify and/or validate 
pharmacological activities; phytochemical analysis to determine chemical components; 
HPLC study to characterize the plants, toxicological studies and so on. The main purpose of 
the above studies may be to enhance the efficacy and the safety profile of the medicinal 
plants and to increase the acceptability of this type of medicine in the society. In the current 
study, some of the above mentioned research methods were employed. 
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CHAPTER 2 
LITERATURE REVIEW 
2.1 Diarrhoea 
2.1.1 General 
Diarrhoea is a condition of having three or more loose or liquid stools per day (Kasper et al., 
2005). It is a common cause of death in Third World Countries and the second most known 
cause of children deaths worldwide (Weber, 1996; WHO, 2009). The loss of fluid and 
electrolytes through diarrhoea can cause dehydration and electrolyte imbalances. In 2009, 
diarrhoea was estimated to have caused 1.1million deaths in people aged 5 years and over, 
and 1.5 million deaths in children under the age of 5 years. Oral rehydration solutions are the 
treatment of choice and have been estimated to have saved 50 million children in the past 25 
years (Kasper et al., 2005; Wilson,2005; WHO, 2009a).  
Diarrhoea due to infection, may last a few days or several weeks, as in persistent diarrhoea. 
Severe diarrhoea may be life threatening due to fluid loss in watery diarrhoea, particularly in 
infants and young children, the malnourished and people with impaired immunity.  The 
impact of repeated or persistent diarrhoea on nutrition and the effect of malnutrition on 
susceptibility to infectious diarrhoea, can be linked to a vicious cycle amongst children, 
especially in developing countries. It is also associated with other infections such malaria and 
measles. Chemical irritation of the gastrointestinal tract or non-infectious bowel disease can 
also result in diarrhoea (Kasper et al.,2005; Wilson,2005; WHO, 2009). 
Diarrhoea is caused by a host of bacterial, viral and parasitic organisms most of which can be 
spread by contaminated water. It is more common where there is a shortage of clean water for 
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drinking, cooking and cleaning, and basic hygiene is important in prevention. Water 
contaminated with human faeces, for example, from municipal sewage, septic tanks and 
latrines is of special concern. Animal faeces also contain micro-organisms that can cause 
diarrhoea. It can also spread from person to person, aggravated by poor hygiene. Food is 
another major cause of diarrhoea when it is prepared or stored in unhygienic conditions. 
Water can contaminate food during irrigation, and fish and seafood from polluted water may 
also contribute to the disease. Worldwide, around 1.1 billion people lack access to improved 
water and 2.4 billion people have no basic sanitation. These will increase susceptibility to 
diarrhoea (Kasper et al., 2005; Wilson, 2005; WHO, 2009). 
2.1.2 Types and causes of Diarrhoea 
Secretory diarrhoea means that there is an increase in the active secretion, or there is an 
inhibition of absorption. There is little or no structural damage. The most common cause of 
this type of diarrhoea is cholera which stimulates the secretions of fluids into the 
gastrointestinal tract (GIT) following an increase in salt secretion like sodium chloride. The 
increase in the fluid buildup in the GIT lumen stimulates peristalsis resulting in watery 
diarrhoea (King et al.,2003;Wilson, 2005; Kasper et al., 2005). 
Osmotic diarrhoea occurs when too much water is drawn into the GIT lumen. This can be the 
result of malabsorption caused by pancreatic disease, in which the nutrients and salts like 
sodium chloride are left in the GIT lumen to pull in water. Osmotic diarrhoea can also be 
caused by osmotic laxatives used in the treatment of constipation (Wilson, 2005; Kasper et 
al., 2005). 
Exudative diarrhoea occurs with the presence of blood or pus in the stools. This occurs with 
 
inflammatory diseases such as Crohn’s disease or ulcerative colitis (Wilson, 2005; Kasper et  
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al., 2005). 
 
 
Inflammatory diarrhoea occurs when there is damage to the mucosal lining, which leads to 
passive loss of protein rich fluids and a decreased ability to absorb these loss fluids. Features 
of all three types of diarrhoea can be found in this type of diarrhoea. This type of diarrhoea 
can be caused by bacterial, viral, parasitic infections or autoimmune problems such as 
inflammatory bowel syndrome. It can also be caused by tuberculosis, colon cancer and 
enteritis (Kasper et al., 2005; Wilson, 2005). 
Generally, if there is blood visible in the stools, it is referred to as dysentery which is a 
symptom of bacterial invasion of the colon by a shigella organism (Kasper et al., 
2005;Wilson, 2005). 
2.1.3 Treatment of Diarrhoea 
Most episodes of diarrhoea are acute and self limiting and may reflect food intolerance, 
bacterial toxin infection or enteric infection. The first line management is the prevention or 
treatment of fluid and electrolyte depletion. This is particularly important for infants, children 
and the frail elderly and may be achieved by either homemade or commercially available oral 
rehydration solutions (Kasper et al., 2005;Wilson, 2005). 
2.1.4 Drug treatment 
Drugs may be used in the management of diarrhoea. The different kinds of antidiarrhoeal 
drugs include anti-propulsives, anti-infectives; intestinal absorbents and anti-inflammatory 
drugs (Kasper et al., 2005;Wilson 2005). 
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2.1.4.1 Anti-propulsive 
 
2.1.4.1.1   Loperamide 
 
Loperamide is an opioid-receptor agonist and acts on the μ-opioid receptors in the myenteric 
plexus of the large intestine; by itself it does not affect the central nervous system like other 
opioids. It works by decreasing the activity of the myenteric plexus, which, like morphine, 
decreases the tone of the longitudinal smooth muscles but increases tone of circular smooth  
muscles of the intestinal wall. This increases the amount of time substances stay in the  
intestine, allowing for more water to be absorbed out of the feacal matter. Loperamide also  
decreases colonic mass movements and suppresses the gastrocolic reflex. It may also reduce  
gastrointestinal secretions. It is given by mouth as an antidiarrhoeal drug and as an adjunct in  
the management of acute or chronic diarrhoea and is usually obtainable as 2 mg tablets or 1 
mg/5 ml syrup. About 40% of the dose of loperamide is reported to be absorbed from the  
gastrointestinal tract to undergo first-pass metabolism in the liver and excretion in the  
faeces via the bile inactive conjugate, there is slight urinary excretion. Little intact drug  
reaches the system circulation. The elimination half life is reported to be 1 hour (Altman,  
2001; Kasper et al., 2005;Wilson, 2005, Waller et al., 2005). 
 
In acute diarrhoea, the usual dose for adults is 2 tablets immediately followed by 1 tablet after 
each loose stool to a maximum of 8 tablets per day, the usual daily dose is 3 to 4 tablets. In 
children the dose is 5 ml three to four times a day up to 3 days (Kasper et al., 2005; Wilson, 
2005; SAMF, 2010).  
In chronic diarrhea, the usual dose for adults is 2 to 4 tablets daily in divided doses 
subsequently adjusted as necessary. The major side effects for loperamide are abdominal 
pain, bloating, nausea, dry mouth, dizziness, and fatigue and hypersensitivity reactions like  
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skin rashes. Loperamide has been associated with paralytic ileus particularly in infants and 
 
young children and death has been reported. Depression of CNS, to which children may be 
 
more sensitive, may be seen in over dosage and naloxone hydrochloride has been  
 
recommended for its treatment (Martindale, 2005, SAMF, 2010). 
 
Loperamide should not be used when inhibition of peristalsis is to be avoided, in particular 
where ileus or constipation occurs, and should be avoided in patients with abdominal 
distension, acute inflammatory bowel disease or antibiotic-associated colitis. It should not be 
used alone in patients with dysentery because dysentery is caused by bacteria and therefore, 
an antibiotic use is necessary. Loperamide should be used with caution in patients with 
hepatic impairment because of its considerable first-pass metabolism in the liver and should 
not be used in infants. Concomitant use with co-trimoxazole increases the bioavailability of 
loperamide, apparently by inhibition of the first-pass metabolism (Martindale 2005).It is 
considered safe for use by breast feeding mothers as there has not been any report of clinical 
effect on the infant associated with its use (Kasper et al., 2005;Wilson,2005). 
2.1.4.1.2  Diphenoxylate 
Diphenoxylate hydrochloride is a synthetic derivative of pethidine with little or no analgesic 
activity. It reduces the intestinal motility and is used in the symptomatic treatment of acute or 
chronic diarrhea. It is well absorbed from the gastrointestinal tract and is rapidly and 
extensively metabolized in the liver principally to diphenoxylic acid, which has antidiarrhoeal 
activity. Other metabolites include hydroxydiphenoxylic acid. It is excreted mainly as 
metabolites and their conjugates in the faeces and lesser amounts in urine. It may be 
distributed in breast milk (Martindale, 2005; SAMF, 2010). 
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In acute diarrhea, the usual dose for adults is 10mg by mouth followed by 5mg every 6 hours, 
later reduced as the diarrhoea is controlled. Suggested initial doses for children 4 to 8 years of 
age, are 2.5mg three times a day; 9 to 12 years, 2.5mg four times a day and over 12 years, 
5mg three times a day. Similar initial doses are used for chronic diarrhoea and subsequently, 
reduced as necessary (Martindale, 2005; SAMF, 2010). 
Diphenoxylate is related to opioid analgesics and its adverse effects and their treatment are 
similar, particularly in overdosage. The reported side effects include anorexia, nausea, 
vomiting, abdominal distension or discomfort, paralytic ileus, toxic megacolon, pancreatitis, 
headaches, drowsiness, restlessness, euphoria, depression, numbness of extremities, 
angioedema, pruritus and swelling of the gums. Signs of overdosage may be delayed and 
patients should be observed for at least 48 hours. Young children are particularly susceptible 
to effects of overdosage (Kasper et al., 2005; Wilson, 2005; Martindale, 2005). 
The presence of subclinical dose of atropine in preparation containing diphenoxylate may 
give rise to the side effects of atropine, such as blurred vision, constipation, flushing, urinary 
retention, tachycardia, mental confusion and agitation, in susceptible individual or in 
overdosage, thereby, acting as a preventive measure to potential abuse (Kasper et al., 2005; 
Wilson, 2005; Martindale, 2005; SAMF, 2010). 
Diphenoxylate hydrochloride should be avoided in patients with jaundice, intestinal 
obstruction; antibiotic associated colitis or diarrhoea associated with enterotoxin-producing 
bacteria and should be used with caution in patients with hepatic impairment.  It should also 
be used with caution in young children because of a greater variability of response in this age 
group and is not generally recommended in infants. Patients with inflammatory bowel disease 
receiving diphenoxylate should be carefully observed for signs of toxic megacolon  
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and it should be discontinued immediately should abdominal distention occur (Martindale, 
2005). 
There is a theoretical risk of hypertensive crisis if it is used with monoamine oxidase 
inhibitors (MAOI’s) due to its structural relationship with pethidine (Kasper et al., 2005; 
Wilson, 2005; Martindale, 2005). 
 
2.2 Diabetes mellitus  
Diabetes mellitus, often simply referred to as diabetes, is a chronic condition in which a 
person has a high glucose level as a result of the body either not producing enough insulin or 
because the body cells do not properly respond to the insulin that is produced. Insulin is a 
hormone produced by pancreatic beta cells in the Islet of Langerhans, which enables body 
cells to absorb glucose which is turned into energy.  If the body cells do not absorb the 
glucose, the glucose accumulates in the blood leading to various potential medical 
complications. (WHO, 1999; Wild et al., 2004; Rother, 2007) 
There are many types of diabetes, the most common of which are: 
a) Type 1 Diabetes or Insulin Dependent Diabetes Mellitus (IDDM) results from the 
body's failure to produce insulin, and presently, requires the person to inject insulin.  
b) Type 2 Diabetes or Non insulin Dependent Diabetes Mellitus (NIDDM) results from 
insulin resistance, a condition in which cells fail to use insulin properly, sometimes 
combined with an absolute insulin deficiency.  
c) Gestational Diabetes is when pregnant women, who have never had diabetes before,  
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have a high blood glucose level during pregnancy. It may precede development of 
Type 2 diabetes mellitus. 
Other forms of diabetes include congenital diabetes, which is due to genetic defects of insulin 
secretion, cystic fibrosis-related diabetes and steroid diabetes induced by high doses of 
glucocorticoids (WHO, 1999; Wild etal., 2004; Rother, 2007). 
Acute complications of diabetes include hypoglycaemia, ketoacidosis and long term 
complications like cardiovascular diseases, retinal complications and angina. Adequate 
treatment of diabetes is thus important, as well as blood pressure control and lifestyle factors 
such as smoking ceasation and maintaining a healthy body weight (Wild etal., 2004; Rother, 
2007) 
As of 2000, at least 171 million people worldwide suffered from diabetes, or 2,8 % of the 
population. Type 2 diabetes is by far the most common, affecting 90 to 95% of the US 
diabetes population (WHO, 1999). 
2.2.1 Classification 
Most cases of diabetes mellitus fall into the three broad categories of Type 1 or Insulin 
Dependent Diabetes Mellitus (IDDM), Type 2 or Noninsulin Dependent Diabetes Mellitus 
(NIDDM) and Gestational diabetes. 
2.2.1.1 Type 1 Diabetes Mellitus (IDDM) 
Type 1 diabetes mellitus is characterized by loss of the insulin-producing beta cells of the 
 
Islets of Langerhans in the pancreas which leads to insulin deficiency. The loss of these cells  
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can be the results of autoimmune disease where the body’s T-cell attack the pancreatic cells  
 
or the results of which is unknown, thereby classified as idiopathic in origin. IDDM  
 
causesapproximately10% of DM cases worldwide and there is no known preventive  
 
measures against it and it affects people of all ages including children (WHO, 1999; Wild et  
 
al., 2004; Rother,2007). 
 
2.2.1.2 Type 2 Diabetes  Mellitus(NIDDM) 
Type 2 diabetes mellitus is characterized by insulin resistance which may be combined with 
relatively reduced insulin secretion. The defective responsiveness of body tissues to insulin is 
believed to involve the insulin receptor. In the early stage of Type 2 diabetes, the 
predominant abnormality is reduced insulin sensitivity. The early stages of type 2 diabetes 
may be managed by medications such as metformin and diet, and as the disease progresses, 
insulin therapy may be necessary  (WHO, 1999; Wild etal., 2004; Rother, 2007).  
2.2.1.3 Gestation Diabetes Mellitus (GDM) 
Gestation diabetes mellitus resembles Type 2 diabetes in several respects, involving 
combination of relatively inadequate insulin secretion and responsiveness. It occurs in about 
2 to 5% of all pregnancies and may improve or disappear after delivery. Gestational diabetes 
is fully treatable but requires careful medical supervision throughout the pregnancy and if left 
untreated, can damage the health of the foetus or mother resulting in high birth weight, 
congenital cardiac or nervous system abnormalities and skeletal muscle malformation. 
About20 to 50% of affected women develop Type 2 diabetes later in life. Increased foetal 
insulin may inhibit foetal surfactant production and cause Respiratory Distress Syndrome 
(Wild etal., 2004). 
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2.2.1.4   Other Types of Diabetes. 
Pre-diabetes indicates a condition that occurs when a person’s blood glucose levels are higher 
than normal but not high enough for a diagnosis of Type 2 diabetes. Many people destined to 
develop Type2 diabetes spend many years in a state of pre-diabetes. Some very uncommon 
cases of diabetes are caused by the body’s tissue receptors not responding to insulin (WHO, 
1999; Rother, 2007). 
2.2.2 Signs and symptoms 
The classical symptoms of diabetes are hyperglycaemia, polyuria, polydipsia and polyphagia. 
The symptoms may develop quite rapidly in Type 1 diabetes particularly in children, 
however, in Type 2diabetes, symptoms usually develop much more slowly and may be subtle 
or completely absent. Type 1 diabetes may also cause a rapid yet significant weight loss and 
persistent mental fatigue. All of these symptoms except weight loss can manifest in Type 2 
diabetes in patients whose diabetes is poorly controlled, although unexplained weight loss 
may be experienced at the onset of the disease (Wild et al., 2004). 
Final diagnosis is made by measuring the blood glucose concentration. When the glucose  
concentration in the blood is high (hyperglycaemia), reabsorption of glucose in the proximal 
convoluted tubule of the kidneys is incomplete resulting in high concentration of glucose in 
the urine (glycosuria).This highconcentration of glucose in the urine results in high osmotic 
pressure which inhibits the reabsorption of water and thereby, resulting in increase urine 
production or polyuria. The resultant lost blood volume will be replaced osmostically from 
water held in body cells and other body compartments causing dehydration and increased 
thirst or polydipsia (Wild et al., 2004). 
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 Prolonged high blood glucose causes glucose absorption, which leads to changes in the 
retinal cells, resulting in vision acuity and eventually blindness; sustained sensible glucose 
control usually returns the lens to its original shape. Blurred vision is a common complaint 
leading to a diabetes diagnosis. Type 1 diabetes should always be suspected in cases of rapid 
vision change, whereas with Type 2 diabetes, change is generally more gradual but should 
still be suspected (WHO, 1999; Wild et al., 2004; Rother, 2007).  
Patients, usually with Type 1 diabetes, may also initially present with diabetic ketoacidosis 
(DKA), an extreme state of metabolic dysregulation characterized by the smell of acetone on 
the patient’s breath, rapid and deep breathing, polyuria, nausea, abdominal pain and any of 
many altered states of consciousness or arousal such as hostility or equally, confusion and 
lethargy. In severe DKA, coma may follow progressing to death. Diabetic ketoacidosis is a 
medical emergency and requires immediate hospitalization (WHO, 1999; Wild et al., 2004; 
Rother, 2007). 
2.2.3 Aetiology 
Type 2 diabetes is determined primarily by lifestyle factors and genes. A number of lifestyle 
factors is known to be important to the development of Type 2 diabetes. People who had high 
levels of physical activity, eat a healthy diet, do not smoke and consumed alcohol in 
moderation have reduced chances of developing Type 2 diabetes. Medical conditions 
associated with Type 2 diabetes are Cushings Syndrome and hypogonadism (Wild etal., 
2004; Rother, 2007). 
Both Type 1 and Type 2 diabetes are partly inherited. Type 1 diabetes may be triggered by 
certain infections with some evidence pointing at Coxsackie B4 virus. There is a genetic  
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element in individual susceptibility to some of these triggers which has been traced to a 
particular HLA (Human Leukocyte Antigen) genotype. However, even in those who have 
inherited the susceptibility, Type 1 diabetes mellitus seems to require an environmental 
trigger. There is a stronger inheritance pattern in Type 2 diabetes. Those with first degree 
relatives with Type 2 diabetics have a much higher risk of inheriting the disease (WHO, 
1999; Wildet al., 2004). 
Gene expression promoted by a diet of fat and glucose as well as high levels of inflammation 
related cytokines found in obese patients results in cells that “produce fewer and smaller 
mitochondria than is normal” and are thus, prone to insulin resistance (Kasper et al., 1998; 
Wild et al., 2004; Rother, 2007). 
2.2.4 Pathophysiology 
Insulin production is more or less constant within the beta cells, irrespective of blood glucose 
levels. It is stored within vacuoles pending release, which is primarily triggered by food, 
chiefly food containing absorbable glucose. The chief trigger is a rise in blood glucose levels 
after eating. Insulin is the principal hormone that regulates the uptake of glucose from the 
blood into most cells. Therefore, deficiency of insulin or the insensitivity of its receptors 
plays a central role in all forms of diabetes mellitus (Nathan et al., 2005; Santaguida, 2008). 
Humans are capable of digesting some carbohydrates, in particular those most common in 
food; starch, and some disaccharides such as sucrose, are converted within a few hours to 
simpler forms most notably the monosaccharide glucose, the principal carbohydrate energy 
source used by the body. The most significant exceptions are fructose, most disaccharides, 
except sucrose and in some people lactose, and all more complex polysaccharides, with the 
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outstanding exception of starch. The rest are passed on for processing by gut flora largely in 
the colon. Insulin is released into the blood by beta cells found in the Islets of Langerhans in 
the pancreas, in response to rising levels of blood glucose, typically after eating. Insulin is 
used by about two-thirds of the body's cells to absorb glucose from the blood for use as fuel, 
for conversion to other needed molecules, or for storage (Nathan, et al 2005; Santaguida, 
2008). 
Insulin is also the principal control signal for conversion of glucose to glycogen for internal 
storage in liver and muscle cells. Low glucose levels result both in the reduced release of 
insulin from the beta cells and in the reverse conversion of glycogen to glucose when glucose 
levels fall. This is mainly controlled by the hormone, glucagon, which acts in the opposite 
manner to insulin. Glucose thus forcibly produced from internal liver cell stores (as glycogen) 
re-enters the bloodstream because muscle cells lack the necessary export mechanism to 
transport glucose to other body tissues. Normally, liver cells do this when the level of insulin 
is low (Nathan et al., 2005; Santaguida, 2008). 
Higher insulin levels increase some anabolic  processes such as cell growth and duplication, 
protein synthesis, and fat storage. Insulin (or its lack) is the principal signal in converting 
many of the bidirectional processes of metabolism from a catabolic to an anabolic direction, 
and vice versa. In particular, a low insulin level is the trigger for entering or leaving ketosis. 
If the amount of insulin available is insufficient, if cells respond poorly to the effects of 
insulin, insulin insensitivity or resistance, or if the insulin itself is defective, then glucose will 
not have its usual effect and will not be absorbed properly by those body cells that require it 
nor will it be stored appropriately in the liver and muscles. The net effect is persistently high  
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levels of blood glucose, poor protein synthesis, and other metabolic derangements, such as 
acidosis(Nathan et al., 2005; Santaguida, 2008). 
2.2.5 Diagnosis 
Diabetes mellitus is characterized by recurrent or persistent hyperglycemia, and is diagnosed 
by demonstrating any one of the following:  
a) Fasting plasma glucose level at or above 7.0 mmol/l.  
b) Plasma glucose at or above 11.1 mmol/l two hours after a 75 g oral glucose load as in 
a glucose tolerance test.  
c) Symptoms of hyperglycemia and casual plasma glucose at or above 11.1 mmol/l.  
d) Glycated hemoglobin (HbA1C) at or above 6.5%.  
About a quarter of people with new Type 1 diabetes have developed some degree of diabetic 
ketoacidosis by the time the diabetes is recognized. The diagnosis of other types of diabetes is 
usually made in other ways. These include ordinary health screening; detection of 
hyperglycemia during other medical investigations; and secondary symptoms such as vision 
changes or unexplainable fatigue. Diabetes is often detected when a person suffers a problem 
that is frequently caused by diabetes, such as a heart attack, stroke, neuropathy, poor wound 
healing or a foot ulcer, certain eye problems, certain fungal infections, or delivering a baby 
with macrosomia or hypoglycemia. A positive result, in the absence of unequivocal 
hyperglycemia, should be confirmed by a repeat of any of the above-listed methods on a 
different day. According to the current definition, two fasting glucose measurements of above 
7.0 mmol/l considered diagnostic for diabetes mellitus (WHO, 1999; Santaguida, 2008). 
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Patients with fasting glucose levels from 5.6 to 6.9 mmol/l are considered to have impaired 
fasting glucose. Patients with plasma glucose at or above 7.8 mmol/l, but not over 
11.1 mmol/l, two hours after a 75 g oral glucose load are considered to have impaired glucose 
tolerance. Of these two pre-diabetic states, the latter in particular is a major risk factor for 
progression to full blown diabetes mellitus as well as cardiovascular disease (Kasper et al., 
1998; WHO, 1999; Santaguida, 2008).  
2.2.6  Screening 
Diabetes screening is recommended for many people at various stages of life, and for those 
with any of several risk factors. The screening test varies according to circumstances and 
local policy, and may be a random blood glucose test, a fasting blood glucose test, a blood 
glucose test two hours after 75 g of glucose, or an even more formal oral glucose tolerance 
test. Many healthcare providers recommend universal screening for adults at age 40 or 50 
years, and often periodically thereafter. Early screening is typically recommended for those 
with risk factors such as obesity, family history of diabetes and high-risk ethnicity (Kasper et 
al., 1998; WHO, 1999; Santaguida, 2008). 
Many medical conditions are associated with diabetes and warrant screening. A partial list 
includes: subclinical Cushing's syndrome, testosterone deficiency, high blood pressure, 
elevated cholesterol levels, coronary artery disease, past gestational diabetes, polycystic 
ovarian syndrome, chronic pancreatitis, fatty liver, hemochromatosis, cystic fibrosis, several 
mitochondrial neuropathies and myopathies, myotonic dystrophy, Friedreich's ataxia and 
some of the inherited forms of neonatal hyperinsulinism. The risk of diabetes is higher with 
chronic use of several medications, including long term corticosteroids, some  
17 
 
 
 
 
chemotherapeutic agents (especially L-asparaginase), as well as some of the antipsychotics 
and mood stabilizers, especially phenothiazines and some atypical antipsychotics.People with 
a confirmed diagnosis of diabetes are tested routinely for complications. This includes yearly 
urine testing for microalbuminuria and examination of the retina of the eye for retinopathy 
(Kasper et al., 1998; Santaguida, 2008). 
2.2.7 Prevention 
2.2.7.1 Type 1 Diabetes Mellitus 
Type 1 diabetes risk is known to depend upon a genetic predisposition based on HLA types, 
an unknown environmental trigger and an uncontrolled autoimmune response that attacks the 
insulin producing beta cells. Children with antibodies to beta cell proteins but no overt 
diabetes, and treated with vitamin B3 (niacin), had less than half the diabetes onset incidence 
in a 7-year time span as did the general population, and an even lower incidence relative to 
those with antibodies as above, but who received no vitamin B3(Kasper et al., 1998, WHO 
1999; Santaguida, 2008).  
2.2.7.2 Type 2Diabetes Mellitus 
Type 2 diabetes risk can be reduced in many cases by making changes in diet and increasing 
physical activity. There is inadequate evidence that eating foods of low glycaemic index is 
clinically helpful despite recommendations and suggested diets emphasizing this approach. 
Diets that are very low in saturated fats reduce the risk of becoming insulin resistant and 
diabetic. Some studies have shown delayed progression to diabetes in predisposed patients 
through prophylactic use of metformin, rosiglitazone or valsartan.  Lifestyle interventions are, 
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however, more effective than metformin at preventing diabetes regardless of weight loss 
(Kasper et al., 1998, WHO, 1999; Santaguida, 2008).  
2.2.8 Management of diabetes mellitus 
Diabetes mellitus is a chronic disease which is difficult to cure. Management concentrates on 
keeping blood sugar levels as close to normal as possible without presenting undue danger to 
the patient. This can usually be with close dietary management, exercise and use of 
appropriate medications. There are roles for patient education, dietetic support, sensible 
exercise, with the goal of keeping both short-term and long-term blood glucose levels within 
acceptable bounds. In addition, given the associated higher risks of cardiovascular disease, 
lifestyle modifications are recommended to control blood pressure in patients with 
hypertension, cholesterol in those with dyslipidaemia, as well as exercising more, smoking 
less or ideally not at all and consuming a recommended diet. Patients with foot problems are 
also recommended to wear diabetic socks and possibly diabetic shoes(Waller et al., 2005a; 
Rother, 2007; Rang et al., 2008). 
2.2.8.1 Drug therapy in the management of diabetes mellitus 
Anti-diabetic drugs treat diabetes mellitus by lowering glucose levels in the blood. With the 
exceptions of insulin, all are administered orally and are thus, also called oral hypoglycemic 
agents or oral anti-hyperglycemic agents. There are different classes of anti-diabetic drugs, 
and their selection depends on the nature of the diabetes, age and situation of the person, as 
well as other factors(Waller et al., 2005a; Rother, 2007; Rang et al., 2008).  
Type 1diabetes mellitus is a disease caused by the lack of insulin. Insulin must be used in  
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Type I diabetes, which must be injected mostly subcutaneously. Type 2 diabetes mellitus is a 
disease of insulin resistance by cells. Treatments include agents that  increase the amount of 
insulin secreted by the pancreas, agents which increase the sensitivity of target organs to 
insulin, and agents which decrease the rate at which glucose is absorbed from the 
gastrointestinal tract(Waller et al., 2005a; Rother, 2007; Rang et al., 2008; SAMF, 2010a).  
Several groups of drugs, mostly given by mouth, are effective in Type 2 diabetes mellitus, 
often in combination. The therapeutic combination in Type 2 diabetes mellitus may include 
insulin, not necessarily because oral agents have failed completely, but in search of a desired 
combination of effects. The great advantage of injected insulin in Type 2 diabetes mellitus is 
that a well-educated patient can adjust the dose, or even take additional doses, as determined 
by the blood glucose levels measured by the patient, usually with a simple meter.(Waller et 
al., 2005a; Rother, 2007; Rang et al., 2008; SAMF, 2010a). 
2.2.8.1.1 Insulin 
Type 1 diabetes mellitus treatments usually include combinations of regular or NPH insulin, 
and/or synthetic insulin analogues. Insulin can be classified into three broad categories; fast 
acting like Novarapid, Apidra, Humalog; intermediate acting like Novomix, Humalog Mix 
and long acting like Levemir and Lantus. The fast acting insulin preparations are usually 
given directly after a meal to provide a bolus dose and the long and intermediate acting 
insulin preparations are given to provide a basal dose for control throughout the day (Rother, 
2007, SAMF, 2010a). 
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2.2.8.1.2 Oral anti-diabetic medications 
i) Sulphonylureas 
Sulphonylureas were the first widely used oral anti-hyperglycaemic medications and are 
insulin secretagogues, triggering insulin release by direct action on the pancreatic beta cells. 
The "second-generation" drugs are now more commonly used. They are more effective than 
first-generation drugs and have fewer side effects. All may cause weight gain. 
Sulphonylureas bind strongly to plasma proteins. Sulfonylureas are only useful in Type 2 
diabetes, as they work by stimulating endogenous release of insulin. They work best with 
patients over 40 years old, who have had diabetes mellitus for underten years. They cannot be 
used in Type 1 diabetes, or diabetes in pregnancy. They can be safely used with metformin or 
glitazones. The primary side effect is hypoglycemia. The reductions in HbA1Cvalues for 
second generation sulphonylureas are 1.0 to 2.0%.First-generation agents are tolbutamide, 
acetohexamide, tolazamide, chlorpropamide and the second generation agents are glipizide, 
glibenclamide, glimepiride and gliclazide(Rother, 2007; SAMF, 2010a). 
ii) Meglitinides 
Meglitinides, which include repaglinide and nateglinide,help the pancreas produce insulin and 
are often called "short-acting secretagogues." They act on the same potassium channels as 
sulphonylureas, but at a different binding site. By closing the potassium channels of the 
pancreatic beta cells, they open the calcium channels, hence enhancing insulin secretion. 
They are taken with or shortly before meals to boost the insulin response to each meal. If a 
meal is skipped, the medication is also skipped. They reduce the HbA1C by approximately  
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0.5 to 1.0%.Adverse reactions include weight gain and hypoglycemia (Waller et al., 2005a; 
Rother, 2007). 
iii) Sensitizers 
Insulin sensitizers address the core problem in Type 2 diabetes, insulin resistance. Among 
oral hypoglycemic agents, insulin sensitizers are the largest category (Rother, 2007). 
iv) Biguanides 
Biguanides reduce hepatic glucose output and increase uptake of glucose by the periphery, 
including skeletal muscle. Although it must be used with caution in patients with impaired 
liver or kidney function, metformin, a biguanide, has become the most commonly used agent 
for type 2 diabetes in children and teenagers. Amongst common diabetic drugs, metformin is 
the only widely used oral drug that does not cause weight gain. The reductions in HbA1C 
values for metformin are 1.5 to 2.0%.Metformin may be the best choice for patients who also 
have heart failure. It should be temporarily discontinued before any radiographic procedure 
involving intravenous iodinated contrast as patients are at an increased risk of lactic acidosis. 
Metformin is usually the first-line medication used for treatment of Type 2 diabetes. It is 
generally prescribed at the initial diagnosis in conjunction with exercise and weight loss as 
opposed to in the past, where metformin was prescribed after diet and exercise had failed. 
Initial dosing is 500 mg once daily, then if need be increased to 500 mg twice daily up to 
1000 mg twice daily. It is also available in combination with other oral anti-diabetic 
medications. There is an extended release formulation available, but it is typically reserved 
for patients experiencing gastro-intestinal side effects. (Waller et al., 2005; Rother, 2007; 
SAMF, 2010a). 
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v) Thiazolidinediones 
This class comprises of rosiglitazone, pioglitazone and troglitazone which was withdrawn 
 
due to hepatitis and liver damage risk.Thiazolidinediones (TZDs), also known as 
 
"glitazones," bind to PPARγ, a type of nuclear regulatory protein involved in transcription of  
 
genes regulating glucose and fat metabolism. These PPARs act on Peroxysome Proliferator  
 
Responsive Elements (PPRE). The PPREs influence insulin sensitive genes, which enhance  
 
production of mRNAs of insulin dependent enzymes. The final result is better use of glucose  
 
by the cells. The typical reductions in HbA1C values are 1.5 to 2.0%. As a result of multiple  
 
retrospective studies, there is a concern about rosiglitazone's safety, although it is established 
that the group, as a whole, has beneficial effects on diabetes. The greatest concern is an 
increase in the number of severe cardiac events in patients taking it (Rother, 2007; SAMF, 
2010a).  
vi) Alpha-glucosidase inhibitors 
The most commonly used alpha-glucosidase inhibitors is acarbose. Alpha-glucosidase 
inhibitors are "diabetes pills" but not technically hypoglycemic agents because they do not 
have a direct effect on insulin secretion or sensitivity. These agents slow the digestion of 
starch in the small intestine, so that glucose from the starch of a meal enters the bloodstream 
more slowly, and can be matched more effectively by an impaired insulin response or 
sensitivity. These agents are effective by themselves only in the earliest stages of impaired 
glucose tolerance, but can be helpful in combination with other agents in Type 2 diabetes. 
The typical reductions in HbA1C values are 0.5 to 1.0%.The major side effects are flatulence  
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and bloating. They do have the potential to cause weight loss by lowering the amount of 
sugar metabolized (Waller et al., 2005a; Rother, 2007). 
viii) Incretin mimetics 
Incretins are insulin secretagogues. The two main candidate molecules that fulfill criteria for 
being an incretin are Glucagon-like peptide-1 (GLP-1) and Gastric inhibitory peptide(GIP). 
Both GLP-1 and GIP are rapidly inactivated by the enzyme dipeptidyl peptidase-4 (DPP-4). 
GLP agonists bind to a membrane GLP receptor. As a consequence of this, insulin release 
from the pancreatic beta cells is increased. Endogenous GLP has a half life of only a few 
minutes; thus an analogue of GLP would not be practical (Rother, 2007). 
Exenatide (also Exendin-4, marketed as Byetta) is the first GLP-1 agonist approved for the 
treatment of Type 2 diabetes. It is not an analogue of GLP, but rather a GLP agonist. 
Exenatide has only 53% homology with GLP, which increases its resistance to degradation 
by DPP-4 and extends its half-life. The typical reductions in A1C values are 0.5 to 1.0% 
(Rother, 2007).  
Liraglutide, a once daily human analogue (97% homology), is being developed by Novo 
Nordisk under the brand name, Victoza. The product was approved by the European 
Medicines Agency (EMEA) on July 3, 2009, and by the U.S. Food and Drug Administration 
(FDA) on January 25, 2010. Taspoglutide is presently in Phase III Clinical Trials with 
Hoffman-La Roche. These agents may also cause a decrease in gastric motility, responsible 
for the common side effect of nausea, and is probably the mechanism by which weight loss 
occurs (Rother, 2007). 
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ix) Gastric inhibitory peptide (GIP) analogs 
None are approved for use in the management of diabetes (Rother, 2007). 
x) DPP-4 inhibitors 
Dipeptidyl peptidase-4 (DPP-4) inhibitors increase blood concentration of the incretin GLP-1 
(glucagon-like peptide-1) by inhibiting its degradation by dipeptidyl peptidase-4 (DPP-4). 
The typical reductions in A1C values are 0.5 to 1.0%. The examples are, vildagliptin, 
sitagliptin  and saxagliptin (Rother, 2007; SAMF, 2010a). 
2.2.9 Prognosis 
Patient education, understanding, and participation are vital since the complications of 
diabetes are far less common and less severe in people who have well-managed blood sugar 
levels. Wilder health problems may accelerate the deleterious effects of diabetes. These 
include smoking, elevated cholesterol levels, obesity, high blood pressure, and lack of regular 
exercise. According to one study, women with high blood pressure were three times more 
likely to develop Type 2 diabetes as compared with women with optimal BP after adjusting 
for various factors such as age, ethnicity, smoking, alcohol intake, body mass index (BMI), 
exercise, family history of diabetes, etc. Except in the case of Type 1 diabetes, which always 
requires insulin replacement, the way Type 2 diabetes is managed may change with age. 
Insulin production decreases because of age-related impairment of pancreatic beta cells 
(Nathan et al., 2005; Rother, 2007).  
Additionally, insulin resistance increases because of the loss of lean tissue and the 
accumulation of fat, particularly intra-abdominal fat, and the decreased tissue sensitivity to 
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insulin. Glucose tolerance progressively declines with age, leading to a high prevalence of 
Type 2 diabetes and post-challenge hyperglycemia in the older population. Age-related 
glucose intolerance in humans is often accompanied by insulin resistance, but circulating 
insulin levels are similar to those of younger people. Treatment goals for older patients with 
diabetes vary with the individual, and take into account health status, as well as life 
expectancy, level of dependence, and willingness to adhere to a treatment regimen. Glycated 
hemoglobin is better than fasting glucose for determining risks of cardiovascular disease and 
death from any cause (Nathan et al., 2005; Rother, 2007). 
In 2000, according to the World Health Organization, at least 171 million people worldwide 
suffer from diabetes, or 2.8% of the population. Its incidence is increasing rapidly, and it is 
estimated that by 2030, this number will almost double. Diabetes mellitus occurs throughout 
the world, but is more common (especially Type 2) in the more developed countries. The 
greatest increase in prevalence is, however, expected to occur in Asia and Africa, where most 
patients will probably be found by 2030. The increase in incidence of diabetes in developing 
countries follows the trend of urbanization and lifestyle changes, perhaps most importantly a 
"Western-style" diet. This has suggested an environmental (i.e., dietary) effect, but there is 
little understanding of the mechanism(s) at present, though there is much speculation, some 
of it most compellingly presented (Nathan et al., 2005; Rother, 2007; WHO, 2010). 
2.2.10. Description and objective of the project. 
Though there are various effective orthodox medicines used to treat diarrhea and diabetes, 
plant medicines have also been used, especially in rural communities, by traditional medicine 
practitioners for the management and treatment of these ailments. One of such plants is  
26 
 
 
 
 
Syzygium cordatum Hochst.ex C.Krauss, also known as ‘water berry’. This plant belongs to 
the family, Myrtaceae, and is locally known as ‘umdoni’ in isiXhosa and Zulu and ‘water 
bessie’ in Afrikaans and ‘montlho’ in South Sotho. It is a medium size tree which can grow 
up to 15 m in height. It has broad leaves which are sometimes, almost circular with a bluish-
green colour (Watt and Breyer-Brandwijk, 1962; Van Wyk et al., 1997). 
The tree is often found near streams, on forest margins or in swampy spots. The leaves, barks 
and roots are used in the form of infusion by traditional medicine practitioners to treat 
diarrhoea, stomach aches, diabetes, respiratory problems, and tuberculosis and so on. It 
flowers from August to November and bears fruits with oval berries which turn from red to 
dark-purple when ripe. It occurs along stream banks from KwaZulu-Natal northwards to 
Mozambique (Watt and Breyer-Brandwijk, 1962; Van Wyk et al., 1997). 
However, little or no scientific evidence exists to corroborate the claims by traditional 
medicine practitioners of the therapeutic successes of the plant species in the treatment of the 
various ailments particularly diarrhoea and diabetes. The present study, therefore, 
investigated the effects of the leaf aqueous extract of Syzygium cordatum on castor oil-
induced diarrhoea in mice and streptozotocin-induced diabetes in rats. The effects of the leaf 
aqueous extract of the plants species on the gastrointestinal transit of charcoal meal and 
castor oil-induced intraluminal fluid accumulation in mice were also investigated. The 
phytochemical analysis of the plant species was carried out to determine the chemical 
components and the acute toxicity investigated to determine the safety profile of the plant 
species. 
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CHAPTER 3 
MATERIALS AND METHODS 
3.1  Plant materials 
Fresh leaves of Syzygium cordatum were collected from Kirstenbosch National Botanical 
Gardens, Cape Town, South Africa in February 2009. The identification of the plant species 
was done by both the curator of the Gardens and Mr Franz Weitz, a taxonomist in the 
Department of Biodiversity and Conservative Biology, University of the Western Cape and a 
voucher specimen (SC8231) was deposited in the Herbarium of the University. 
3.2  Preparation of leaf aqueous extract of Syzygium cordatum 
The fresh leaves of the plant species were weighed (1.4 kg), washed with distilled water and 
dried at 35OC for 4 days. The dried leaves (857 g) were ground to fine powder. 80 grams of 
the fine powder was refluxed in 1 l of boiling water, allowed to cool and filtered. The filtrate 
was then frozen at – 80OC and freeze-dried for 5 days. A yield of 19.57g of dried leaf 
aqueous extract was obtained and stored in a dessicator for future use. Fresh extract solutions 
were prepared every day for the experiment by dissolving weighed quantities of the extract in 
physiological saline. The solutions were administered orally to mice or rats in a volume of 
1ml/100g of animal using bulbed steel needle. 
 3.3 Drugs and Chemicals 
Castor oil (GR Pharmaceuticals (Pty) Ltd, Atlantis, South Africa) was administered orally in 
a constant volume to mice throughout the experiments using bulbed steel needle. Lopermaide 
( 4[p-chlorophenyl] – 4 – hydroxy-N,N-dimethyl- diphenyl-1-piperidine-butyramine) 
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hydrochloride (Sigma Chemical Co) was dissolved in a minimum amount of 10% ethanol 
(Merck (Pty) Ltd) and made up to the appropriate volume with physiological saline. 
Activated charcoal (Sigma Chemical Co), an aqueous suspension of 5% charcoal and 5% 
acacia, was prepared. Both the loperamide solution and the charcoal meal were given orally 
to mice in volume of 1ml/100g of animal using a bulbed steel needle. Streptozotocin (STZ, 
Sigma Chemical Co.) was dissolved in a small volume of 0.1 M citrate buffer pH 4.5, and 
made up to the appropriate volume with physiological saline, and administered 
intraperitoneally to rats in a volume of 1ml/100g animals. Chlorpropamide (Sigma Co.) was 
dissolved in physiological saline and administered orally to rats in a volume of 1ml/100g of 
animal using a bulbed steel needle. 
3.4 Animals 
Male albino mice bred in the Animal House of the Discipline of Pharmacology, University of 
the Western Cape, South Africa and weighing 18 – 30g were used for the antidiarrhoeal 
activity and the acute toxicity testing of the plant species. Young adult male Wistar rats, 
bought from the University of Cape Town, South Africa and weighing 160 – 210g were used 
for the antidiabetic activity. The animals were housed in a quiet laboratory with an ambient 
temperature of 22  2OC and a 12- h light/12-h dark cycle was maintained. They were all 
maintained on a standard pellet diet and water ad libitum. All the animals were fasted for 16 h 
during which they had free access to water prior to the commencement of the experiments. 
3.5 Assessment of antidiarrhoeal activity 
Male albino mice, weighing between 18 and 30g, were used in groups of six per dose of plant 
extractor loperamide, a standard antidiarrhoeal drug, throughout the experiments after 
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fasting for 16 hours. The method described by Williamson et al. (1996) was modified and 
used to assess the antidiarrhoeal activity of the plant extract. Castor oil, a laxative, known to 
cause diarrhoea within 4 h, was used to induce diarrhoea in a control group of mice pre-
treated with 0.3ml (p.o.) of physiological saline for 15 min prior to the oral administration of 
0.7ml of castor oil. The onset of diarrhoea, the number of diarrhoeal episodes, stool mass and 
the number of mice exhibiting diarrhoea were obtained over a 5 h period of observation. 
Experiments were repeated with other groups of animals (test groups),  pretreated for 15 min 
with either leaf aqueous extract (3.125 – 50 mg/kg) of the plant species or the standard 
antidiarrhoeal drug, loperamide (20 mg/kg), both given orally in a volume of 1 ml/100g of 
animals prior to the administration of 0.7 ml (p.o.) of castor oil. The ability of the plant 
extract to reduce the number of animals exhibiting diarrhoea and /or the number of diarrhoeal 
episodes is taken as an antidiarrhoeal activity (Williamson et al., 1996). The doses and 
pretreatment times used were obtained from preliminary studies in our laboratory. All 
experiments were carried out between 080:00 and 17:00 in a quiet laboratory with an ambient 
temperature of 22 2OC. 
3.6  Assessment of gastrointestinal propulsion of charcoal meal. 
The methods used to assess the effect of the plant extract on the gastrointestinal transit of 
charcoal meal were those described by Williamson et al. (1996) and Kitano et al. 
(1994).Animals were used in groups of six per dose of leaf aqueous plant extract (3.125 – 50 
mg/kg, p.o.) or loperamide (20 mg/kg, p.o.), a standard antidiarrhoeal drug after fasting for 
16 h. Control group was pretreated with 0.3ml of physiological saline given orally, for 20 min 
and then given 0.4ml of charcoal meal (aqueous suspension of 5% charcoal and 5% gum 
acacia)  
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orally. 20 min after the charcoal meal, the animals were killed by ether inhalation and the 
intestine was removed from the cardia to the rectal end. The distance travelled by the 
charcoal meal was measured and expressed as a percentage of the total length of the intestine. 
Experiments were repeated with other groups of animals (test groups) pretreated with the leaf 
aqueous plant extract (3.125 – 50 mg/kg) or loperamide (20 mg/kg), both given orally in a 
volume of 1ml/100g of animals, prior to the administration of 0.4ml of charcoal meal. All 
experiments were carried out between 08:00 and 17:00 in a quiet laboratory with the ambient 
temperature of 22  2OC. 
3.7 Assessment of castor oil-induced intestinal fluid accumulation. 
The methods of Robert et al. (1976) and DiCarlo et al. (1994) were modified and used to 
assess the effect of the plant extract on castor oil-induced intestinal fluid accumulation. The 
animals were used in groups of six per dose of leaf aqueous plant extract (3.125 – 50 mg/kg, 
p.o.) or loperamide (20 mg/kg, p.o.), a standard antidiarrhoeal drug, after fasting for 16 hours. 
The control group of six mice was pretreated with 0.3ml (p.o.) of physiological saline for 15 
min and then given 1.5ml of castor oil orally. 20 minutes after the administration of castor 
oil, the animals were killed by ether inhalation and the intestines removed from the pylorus to 
the caecum. The intestinal contents were then evacuated into a measuring cylinder and the 
volume measured. Experiments were repeated with other groups of animals pretreated for 15 
min with the leaf aqueous plant extract (3.125-50 mg/kg) or loperamide (20 mg/kg), a 
standard antidiarrhoeal drug, both given orally in a volume of 1ml/100g of animals, prior to 
the oral administration of 1.5 ml of castor oil.All experiments were carried out between 08:00 
and 17:00 in a quiet laboratory with an ambient temperature of 22 2OC. 
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3.8   Assessment of antidiabetic activity 
Modified methods of Williamson et al. (1996a) and Joy and Kuttan (1999) were used to 
assess the antidiabetic activity of the leaf aqueous extract of Syzygium cordatum. Rats in 
groups of six each were divided into normoglycaemic and diabetic rats. The normoglycaemic 
rats were further divided into ‘control and test’ groups. The control group of six rats received 
0.3 ml of physiological saline orally while five groups (of six rats each) of test rats were 
treated with the leaf aqueous extract of Syzygium cordatum (3.125 – 50 mg/kg, p.o.). One 
group of six test rats received chlorpropamide (250 mg/kg, p.o.), a standard antidiabetic drug. 
Similarly, the diabetic rats were divided further into ‘control and test’ groups. Diabetes was 
induced in all the diabetic rats by intraperitoneal injections of streptozotocin (STZ, 90 
mg/kg). Following the injection, diabetes was allowed to develop and stabilize in the rats 
over a period of 3 – 5 days. The diabetic control group received 0.3 ml of physiological saline 
orally. Five groups of test diabetic rats received the leaf aqueous extract of the plant species 
(3.125 – 50 mg/kg, p.o.) whereas one group of test diabetic rats received chlorpropamide 
(250 mg/kg0, p.o.). In both normoglycaemic and diabetic rats, blood glucose levels were 
measured first without treatment (0 h) and then, the animals received either 0.3 ml (p.o.) of 
physiological saline, plant extract (3.125 – 50mg/kg, p.o.) or chlorpropamide (250 mg/kg, 
p.o.) after which the blood glucose levels were measured at intervals of 1 h, 2 h and 4 h in 
each treatment group. The blood samples for  the measurement of the glucose levels were 
obtained by pricking of the rat tail tip vein. A drop of blood was placed on a glucose test strip 
and the glucose level read using a compatible Glucometer ( Accu-Check Abbot 
laboratory). The blood was obtained from both normoglycaemic and diabetic rats before 
treatment (0 h) and then 1 h, 2 h,  
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and4 h after treatment with either physiological saline, plant extract or chlorpropamide. Each 
glucose test strip was used only for one reading. Fasted streptozotocin–treated rats with blood 
glucose level greater than or equal to 18 mmol/l were considered diabetic). The ability of the 
plant extract to significantly lower the blood glucose level below 18 mmol/l is taken as an 
antidiabetic activity (Williamson et al., 1996a; Joy and Kuttan, 1999). 
3.9   Acute toxicity testing 
Male albino mice were used in groups of six per dose of plant extract after fasting for 16 h. 
The method of Lorke (1983) was modified and used to assess the acute toxicity of the leaf 
aqueous extract of Syzygium cordatum. The plant extract was administered orally to mice in 
graded doses ( 200, 400, 800, 1200, 1600, 2000, 2400, 2800, 3200, 3600 and 4000 mg/kg). 
Another group of six mice used as control, received 0.3 ml physiological saline orally. Both 
the test and control animals were then allowed access to food and water and observed over a 
period of 5 days for any deaths or acute toxicity symptoms such as hypoactivity, piloerection, 
salivation and so on. The log dose/response (% death) curve may be plotted  depending on 
the result obtained from which the median lethal dose (LD50) of the plant extract would be 
obtained. 
3.10  Phytochemical analysis of Syzygium cordatum 
The phytochemical analysis was performed using the methods of Ikhiri et al. (1992) 
 
and Harborne (1984) to screen for chemical compounds including alkaloids, 
 
flanonoids, saponins,tannins, reducing sugars and triterpene steroids, present in the leaves of  
 
Syzygium cordatum. 
 
3.10.1 Alkaloids 
 
0.5 g of the dried and powdered S. cordatum leaves was boiled with 10 ml of dilute  
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hydrochloric acid (alcoholic) in a test tube for 5 min. The mixture was cooled and the debris  
 
allowed to settle. The supernatant liquid was filtered and 1ml of this filtrate taken into  
 
another test tube to which three drops of Dragendorff’s reagent were added, shaken and  
 
observed for formation of an orange-reddish precipitate which wouldindicate the presence of  
 
alkaloids. 
 
3.10.2 Triterpene steroids 
 
1 g of the powdered leaf of S. cordatumwas extracted for 24 hours in ether. The resultant 
 
solution was filtered and I ml of the filtrate evaporated to dryness. The resultant residue 
 
was re-dissolved in several drops of acetyl anhydride to which several drops of dilute 
 
sulphuric acid were added and observed for a green colour change which would 
 
indicate the presence of triterpene steroids. 
 
3.10.3 Reducing sugars 
 
0.2 g of the powdered leaf of S. cordatum was boiled with 5 ml water, the mixture cooled and  
 
filtered. To the filtrate, an equal amount of Fehling’s solutions A and B in a ratio 1:1 was  
 
added and the mixture was heated on a water bath, and observed for a red-brown precipitate  
 
which would indicate the presence of reducing sugars. 
 
3.10.4 Saponins 
 
0.4 g of the powdered plant material was shaken with 4 ml of water in a clean test tube 
 
and observed for a persistent froth (foam) which would indicate the presence of 
 
saponins. 
 
3.10.5 Tannins 
 
0.2 g of the powdered plant material was boiled in 5 ml of water, the subsequent 
 
mixture was allowed to cool and filtered thereafter. To the filtrate, 2-3 drops of 5% 
 
ferric chloride solution were added and observed for a blue-black precipitate which 
 
would indicate the presence of tannins. 
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3.10.6 Quinones 
 
10 g of S. cordatum leaf powder was moistened with a 10 % hydrochloric acid (HCl) solution  
 
and allowed to stand in ether: chloroform mixture (3:1, 40 ml). The mixture was filtered and  
 
1 ml of the resultant extract treated with 1 ml 10 % sodium hydroxide (NaOH) solution. A  
 
red discoloration would indicate the presence of quinones. 
 
3.10.7  Flavonoids 
 
5 g of S. cordatum powdered leaf was boiled in water bath for 3 min, cooled and filtered. 3  
 
ml of acid-alcohol (ethanol:water:concentrated HCL, 1:1:1), was added to 3 ml of the filtrate.  
 
A small piece of solid magnesium and 1 ml of t-amyl alcohol where also added to the  
 
mixture. A rose-orange or violet colour would indicate the presence of flavonoids. 
 
 
 
3.11  Statistical Analysis 
 
The data obtained from the antidiarrhoeal and antipropulsive activity and intestinal fluid  
accumulation experiments as well as the antidiabetic activity were analysed using one-way  
analysis of variance (ANOVA) followed by Dunnett’s multiple comparison (GraphPad 
Prism, version 5.0, GraphPad Software, Inc., San Diego CA 92130, USA) and presented as  
meanstandard error of mean (SEM). However, the data on the number of animals exhibiting  
diarrhoea were analysed using the Chi square test. In the above cases, P values of less than  
5% (P<0.05), were considered to be significant. 
 
 
3.12  Ethics clearance 
The Ethics Committee of the University of the Western Cape approved the experimental  
Protocol (07/04/31) used in the present study and this conforms to the “Guide to the care and  
use of animals in research and teaching” of the University. 
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CHAPTER 4 
RESULTS 
4.1 Effect of leaf aqueous extract of Syzygium cordatum on castor-oil induced diarrhoea 
0.7 ml of castor-oil, given orally, produced diarrhoea within 4 h in all the six animals used  
and also produced a considerable amount of stool. Syzygium cordatum (3.125-50 mg/kg, p.o.)  
significantly reduced the faecal output produced by castor oil. S. cordatum in all the doses  
used, reduced the feacal output from 100% produced by castor-oil to between 40 and 61%. S.  
cordatum(6.25-50 mg/kg, p.o.) significantly and in a dose dependent manner, delayed the  
onset of castor oil (0.7 ml, p.o)-induced diarrhoea. Doses of 3.125-50 mg/kg (p.o.) 
significantly reduced castor oil (0.7 ml, p.o.)-induced diarrhoeal episodes but did not  
significantly alter the number of animals exhibiting diarrhoea. Loperamide (20 mg/kg, p.o.) 
significantly reduced the feacal output produced by castor-oil (0.7 ml, p.o.) from 100%  
produced by castor oil to 8.7%. 20 mg/kg (p.o.) of loperamide profoundly delayed the onset  
of diarrhoea produced by castor-oil (0.7 ml, p.o.) and profoundly reduced the incidence of  
castor-oil (0.7 ml, p.o.)-induced diarrhoea by protecting 83% of animals against the  
diarrhoea. Loperamide (20 mg/kg, p.o.) profoundly reduced the number of castor-oil (0.7 ml,  
p.o.)induced diarrhoeal episodes by 96% (Table 1). 
 
4.2  Effect of leaf aqueous extract of Syzygium cordatum on gastrointestinal transit of 
charcoal meal 
The mean length of intestine travelled by 0.4 ml (p.o.) of charcoal meal in control mice  
pretreated with 0.3 ml (p.o.) of physiological saline was 87.73 ± 5.01%. Leaf aqueous extract  
ofSyzygium cordatum (6.25-50 mg/kg, p.o.) significantly and dose dependently decreased the  
meanlength of intestine travelled by 0.4 ml (p.o) of the charcoal mean. The propulsion of the  
charcoal mean was inhibited by 21.25-50.93 at doses of 3.125-50 mg/kg (p.o.) of S.  
cordatum. Loperamide (20 mg/kg, p.o.) significantly reduced the mean length of intestine  
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travelled by charcoal meal (0.4 ml, p.o.). Loperamide (20 mg/kg, p.o.) inhibited the  
propulsion of the charcoal meal by 79.06 (Table 2). 
 
Table 1. Effect of leaf aqueous extract of Syzygium cordatum on castor oil-induced diarrhoea 
in mice 
Treatment Mass of      Faecal Onset of           Number of      Percentage             Number of  
groups       stool           output diarrhoea         diarrhoeal      diarrhoeal episode  animals 
exhibiting 
(mg/kg)         (g)             (%)     (min)             episode          inhibition               diarrhoea 
                Mean±SEM            Mean±SEM     Mean  ± SEM (%) 
PS  
0.3 ml      3.67    0.29    100    22.17   2.10     25.17      0.93                    6/6 
Syzygium  cordatum 
 3.125      2.22**0.14    60.5   42.17    3.90    10.83*** 1.49        56.97          6/6  
 6.25        2.22**0.39    60.5   70.83*  5.67    12.17*** 2.40        51.65          6/6 
12.50       1.80***0.27  49.0   71.50*  4.32      8.00*** 1.05        68.22         6/6 
25.00       1.45***0.28  39.5   79.33*  5.97      5.67*** 1.30        77.47          6/6 
50.00       1.83***0.21  49.9 105.17***19.60  9.83*** 0.96        60.95          6/6 
Loperamide 
20.00       0.32***0.18   8.7  119.83***16.57  1.00*** 0.00        96.02                  1/6+ 
*p<0.01, **p<0.005, ***p<0.001 vs castor oil (0.7 ml, p.o.) control. ANOVA (n=6). 
+p<0.005 vs castor oil (0.7 ml, p.o.) control. Chi-squared test (n=6). 
PS: Physiological saline 
 
4.3 Effect of leaf aqueous extract of Syzygium cordatum on castor oil-induced intestinal fluid 
accumulation 
The mean intestinal fluid volume produced by castor oil (1.5 ml, p.o.) in control animals  
pretreated with physiological saline (0.3 ml, p.o.) was 1.42 ±0.19 ml. Syzygium cordatum 
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Table 2. Effect of leaf aqueous extract of Syzygium cordatum on gastrointestinal transit of 
charcoal meal in mice 
Treatment groups                  Length of intestine travelled   Percentage inhibition in length 
(mg/kg)    (%)             of intestine travelled  
     Mean     ±   SEM   (%) 
PS 
0.3 ml     87.73          5.01    
Syzygium cordatum 
 3.125    69.09 4.87   21.25 
 6.25    63.17*         4.57   28.00 
12.50    62.34*         7.20   28.94 
25.00    58.48**       5.95   33.34 
50.00    43.05***     9.84   50.93 
Loperamide 
20.00    18.37***     3.14   79.06 
*p<0.05, **p<0.005, ***p<0.001 vs charcoal meal ( 0.4 ml, p.o.) control. ANOVA (n=6). 
PS: Physiological saline. 
 
(3.125-50 mg/kg, p.o.)significantly reduced the mean intestinal fluid volume produced by  
 
castor oil (1.5 ml, p.o.). The mean intestinal fluid volume was reduced or inhibited by 41.55- 
 
59.15%. Loperamide (20 mg/kg, p.o.) significantly reduced the mean intestinal fluid volume  
 
produced by castor oil (1.5 ml, p.o.). The mean intestinal fluid volume produced by castor oil  
 
(1.5 ml, p.o.) was inhibited by loperamide (20 mg/kg, p.o.) by 52.82% (Table 3). 
 
 
4.4  Effect of leaf aqueous extract of Syzygium cordatum on blood glucose concentrations 
(mmol/l) of normoglycaemic rats 
 
0.3 ml (p.o.) of physiological saline did not significantly alter the blood glucose concentration  
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Table 3. Effect of leaf aqueous extract of Syzygium cordatum on castor-oil induced intestinal 
fluid accumulation in mice 
Treatment groups                         Intestinal fluid volume                  Percentage inhibition 
(mg/kg)                                                       (ml)                                               (%) 
                                                      Mean    ±    SEM 
PS 
0.3 ml   1.42             0.19 
Syzygium cordatum 
 3.125    0.58**    0.04    59.15 
 6.25                                              0.83*           0.15    41.55 
12.50                                             0.80*           0.02    43.66 
25.00                                             0.80*           0.05    43.66 
50.00                                             0.73*           0.05    48.59 
Loperamide 
20.00                                             0.67**         0.07    52.82 
*p<0.01, **p<0.001 vs castor oil (1.5 ml, p.o.) control. ANOVA (n=6). 
 
of fasted normal rats throughout the 4 h period of observation. Syzygium cordatum (3.125-
6.25 mg/kg, p.o.) did not significantly affect the blood glucose concentration of fasted normal 
rats throughout the 4 h of observation. 12.50-50 mg/kg (p.o.) of Syzygium cordatum 
significantly reduced the blood glucose concentration of fasted normal rats from the second 
to the fourth hour of observation with a percentage maximal reduction of 28.60-32.79%. 
Chlorpropamide (250 mg/kg, p.o.) significantly reduced the blood glucose concentration of 
fasted normal rats from the first hour through the fourth hour of observation and the 
percentage maximal reduction was 43.26% (Table 4). 
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Table 4. Effect of leaf aqueous extract of Syzygium cordatum on blood glucose 
concentrations (mmol/l) of normoglycaemic (normal) rats__________________________ 
Treatment      Before               After treatment                                          Maximal   Percentage 
groups            treatment      ___________________________________ reduction  maximal 
(mg/kg)          0 h                1 h                    2 h                   4 h                                  reduction 
(%) 
PS 
0.3 ml           6.18 ± 0.24     5.82 ± 0.20      5.65 ± 0.18      6.10 ± 0.20      0.53          8.58 
Syzygium cordatum 
3.125 6.67 ± 0.21     5.90 ± 0.13      5.57 ± 0.14      5.72 ± 0.27      1.10         16.49 
6.25              6.75 ± 0.25     6.03 ± 0.21      5.37 ± 0.18      5.80 ± 0.24      1.38         20.44 
12.50            6.33 ± 0.56     5.98 ± 0.22      4.73 ± 0.32*    4.52 ± 0.38**  1.81         28.60 
25.00            6.80 ± 0.20     5.92 ± 0.32      4.75 ± 0.15*    4.60 ± 0.20**  2.20         32.35 
50.00            6.80 ± 0.29     5.58 ± 0.29      4.62 ± 0.12*    4.57 ± 0.42**  2.23         32.79 
Chlopropamide 
250               6.75 ± 0.40     4.85 ± 0.29*    3.83 ± 0.37*** 3.87 ± 0.35*** 2.92       43.26 
*p<0.05, **p<0.01, ***p<0.001 vs physiological saline (0.3 ml, p.o.) control. ANOVA 
(n=6). 
Values are expressed as mean ± SEM. PS: Physiological saline 
 
4.5 Effect of leaf aqueous extract of Syzygium cordatum on blood glucose concentrations 
(mmol/l) of streptozotocin-treated diabetic rats 
Streptozotocin (90 mg/kg, p.o.) raised the blood glucose concentration of fasted animals to 
21.40 ± 1.02 mmol/l. 0.3 ml (p.o.) of physiological saline did not significantly affect the 
blood glucose concentration of fasted diabetic rats throughout the 4 h of observation. 3.125 
mg/kg (p.o.) of Syzygium cordatum did not significantly alter the blood glucose concentration  
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of the fasted diabetic rats throughout the 4 h of observation. Syzygium cordatum (6.25 mg/kg, 
p.o.) significantly reduced the blood glucose of the fasted diabetic rats in the 4th h of 
observation with a percentage maximal reduction of 23.37%. Syzygium cordatum (12.50-25 
mg/kg, p.o.) significantly reduced the blood glucose concentration of fasted diabetic rats from 
the 2nd to the 4th h of observation with a percentage maximal reduction of 33.18-35.54%. 50 
mg/kg (p.o.) of S. cordatum significantly reduced the blood glucose concentration of fasted 
diabetic rats from the 1st h through to the 4th h of observation with a percentage maximal 
reduction of 33.37%. Chlorpropamide (250 mg/kg, p.o.) profoundly reduced the blood 
glucose concentration of fasted diabetic rats from the 1st h through the 4th h of observation 
with a percentage maximal reduction of 93.42% (Table 5). 
4.6 Acute toxicity test 
 
The leaf aqueous extract of Syzygium cordatum (200, 400, 800, 1200, 1600, 2000, 2400,  
 
2800, 3200, 3600 and 4000 mg/kg) administered orally to mice did not cause any death to or  
 
any acute toxicity symptoms in the animals in all the doses used. The highest dose tested  
 
being 4000 mg/kg should be the no-adverse-effect-level (NOAEL). The LD50 value for the  
 
plant species should, therefore, be greater than 4000 mg/kg (p.o.).  
 
 
4.7 Phytochemical analysis 
 
The phytochemical screening methods used to determine the active constituents present 
 
in the leaves of Syzygium cordatum tested positive for alkaloids, tannins, flavonoids, 
 
reducing sugars, triterpene steroids and saponins. However, no quinones were present (Table  
 
6). 
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Table 5. Effect of leaf aqueous extract of Syzygium cordatum on blood glucose 
concentrations (mmol/l) of streptozotocin-treated diabetic rats 
___________________________________________________________________________ 
Treatment  Before               After treatment                 Maximal   Percentage 
groups        treatment      ___________________________________  reduction  maximal 
(mg/kg)      0 h                   1 h                     2 h                        4 h                           reduction  
(%) 
PS 
0.3 ml        21.40 ± 1.02    23.67 ± 1.26      23.67 ± 0.89       23.88 ± 1.00            
Syzygium Cordatum 
3.125 23.37 ± 1.10    23.78 ± 0.66      23.20 ± 0.60       22.95 ± 0.47     0.83       3.49 
6.25           22.68 ± 1.04    22.43 ± 0.52      20.77 ± 0.55       17.38 ± 1.11*   5.30     23.37 
12.50         20.32 ± 0.59    21.28 ± 1.14      15.25 ± 0.78*     14.22 ± 1.80*   7.06     33.18 
25.00         20.17 ± 0.57    21.41 ± 1.53      14.12 ± 0.12*     13.80 ± 0.93*   7.61     35.54         
50.00         20.53 ± 2.08    14.42 ± 0.87*    14.07 ± 0.68*     13.68 ± 0.89*   6.85     33.37        
Chlopropamide 
250            23.23 ± 0.94    15.55 ± 1.34*      6.38 ± 1.12*       4.05 ± 0.24*  19.18    93.42       
*p<0.001 vs streptozotocin (90 mg/kg, i.p.) control. ANOVA (n=6). 
Values are expressed as mean ± SEM. 
PS: Physiological saline 
 
Table 6. Phytochemical screening of the leaf aqueous extract of Syzygium cordatum 
 
Compound       Result    
Tannins        + 
Saponins        + 
Alkaloids        + 
Flavonoids        + 
Triterpene steroids       + 
Quinones        - 
Reducing sugars       +    
+ (positive):   Present,  - (negative): Absent 
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CHAPTER 5 
 
DISCUSSION 
 
Diarrhoea and diabetes are debilitating conditions known to afflict so many people worldwide  
 
and especially on the African continent (Weber,1976; Syder and Merson, 1982; Rother,  
 
2007). Modern or orthodox medicines have provided adequate management and treatment of  
 
the conditions. It is a well established fact that about 80% of the population especially in  
 
developing countries rely on herbal medicines for their healthcare need. The reasons range  
 
from low cost to availability of these medicines and their use depends on ancestral  
 
experience. WHO has also urged various governments especially those of the developing  
 
countries, to include in their healthcare programmes those herbal medicines with proven  
 
safety and efficacy (Marin-Bettolo, 1980; Amos et al., 2001). Syzygium cordatum is one  
 
medicinal plant used by traditional medicine practitioners in South Africa to treat various  
 
ailments including diarrhoea and diabetes (Van Wyk et al., 1997). In order to scientifically  
 
scrutinized the claims by traditional medicine practitioners of the therapeutic success of the  
 
plant species, this project studied the antidiarrhoeal and antidiabetic activities of Syzygium  
 
cordatum in mice and rats respectively. 
 
 
In this study, the plant extract, up to the highest dose (4000 mg/kg, p.o.) used in the acute  
 
toxicity test, did not cause any death to or acute toxicity symptoms in the mice. The LD50,  
 
therefore, may be greater than 4000 mg/kg (p.o.). This relatively high LD50 shows that the  
 
plant extract is non-toxic and/or safe in mice. Traditional medicine practitioners are known to  
 
use the plant for treatment in the form of infusion (Van Wyk et al., 1997). However, this  
 
study did not ascertain the doses used by the practitioners for such treatments. 
 
 
The pharmacological screening results obtained in the present study, show that S. cordatum 
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(3.125-50 mg/kg, p.o.)antagonized the diarrhoea produced by castor oil (0.7 ml, p.o.).  
 
Loperamide (20 mg/kg, p.o.) also antagonized the castor oil-induced diarrhoea in mice. 
 
Castor oil, an irritant laxative, is thought to produce diarrhoea by being hydrolysed in the  
 
upper small intestine to ricinoleic  acid which exerts its effects by irritating the mucosa of the  
 
gastrointestinal tract, resulting in an increase in intestinal motility (Altman, 2001).  
 
Furthermore, ricinoleic acid has been shown to diminish the permeability of sodium and  
 
chloride ions and also stimulate the release of prostaglandin, known to cause diarrhoea  
 
(Gaginella and Phillips, 1975; Zavala et al., 1998).In addition, the works of Capasso et al. 
 
(1994) and Mascolo et al. (1994), on the effect of NG-nitro-L-arginine methyl esther, an  
 
inhibitor of nitric oxide (NO) synthase, on the dissociation of castor oil-induced diarrhoea  
 
and mucosal injury in rat, showed that nitric oxide may mediate castor oil-induced diarrhoea.  
 
 
Loperamide, an opioid derivative and a standard antidiarrhoeal drug, is thought to decrease  
 
intestinal motility by binding to mu receptors on neurons in the submucosal neural plexus of  
 
the intestinal wall. This leads to the segmental contractions in the colon increasing, the  
 
propulsive movement of the small intestine and colon being inhibited and the transit time of  
 
the intestinal content being prolonged (Altman, 2001). Loperamide is also known to have an  
 
antimuscarinic activity contributing to the inhibition of peristalsis by inhibiting contractions  
 
in both the longitudinal and circular muscles (Altman, 2001; Camillen et al., 2002; Waller et  
 
al., 2005). In this study, therefore, loperamide may be antagonizing castor oil-induced  
 
diarrhoea by decreasing the intestinal motility. Similarly, Syzygium cordatum may be said to  
 
exert its antidiarrhoeal activity by slowing intestinal motility.         
 
 
In my study, the leaf aqueous extract of S. cordatum significantly antagonized the  
 
gastrointestinal transit of charcoal meal and also significantly reduced the castor oil-induced  
 
intraluminal accumulation of fluid volume. Similarly, loperamide significantly antagonized  
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the gastrointestinal transit of charcoal meal and also significantly reduced the castor oil- 
 
induced intraluminal accumulation of fluid volume. According to DiCarlo et al. (1994), 
 
agents that reduce intestinal motility and secretion may possess antidiarrhoeal activity.  
 
Furthermore, Nwafor et al. (2000) have shown that agents that suppress intestinal fluid  
 
accumulation may inhibit gastrointestinal functions. The above reports lend support to the  
 
suggestion that S. cordatum may be exerting its antidiarrhoeal activity by slowing intestinal  
 
motility. 
 
 
The phytochemical analysis of the powdered leaf of S. cordatum carried out in this study  
 
showed that the plant species contains the following chemical components, tannins, saponins,  
 
alkaloids, triterpene steroids, flavonoids and reducing sugars. Several studies have shown  
 
tannins to have antidiarrhoeal activity. Tannin containing drugs have been used for the  
 
treatment of diarrhoea and other related disorders (Frei et al., 1998; Bruneton, 1999).  
 
Astringents such as tannins have been known since the last century to have antisecretory  
 
effect in the gastrointestinal tract and have been used to treat diarrhoea (Farthing). It is  
 
probable therefore, that the presence of tannins in the plant species as shown by the  
 
phytochemical analysis, may contribute to the antidiarrhoeal activity of S. cordatum.  
 
 
Syzygium cordatum was shown in the present study to have an antidiabetic activity.  
 
Chlorpropamide, a sulphonylurea, and an oral antidiabetic agent used for the treatment of  
 
Type 2 or non-insulin dependent diabetes (NIDD), was used as a standard drug in this study.  
 
Chlorpropamide is thought to act by stimulating and increasing the release of endogenous  
 
insulin from the pancreatic beta cells of the Islet of Langerhans (Waller et al., 2005a; Rang et  
 
al., 2008). Diabetes, in this study, was induced using streptozotocin (STZ). Streptozotocin is  
 
thought to produce diabetes by a rapid depletion of pancreatic beta cells and thereby,  
 
reducing insulin release and causing hyperglycaemia (Mahomed and Ojewole, 2003). Thus,  
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the STZ-induced rat diabetes model has the hallmark of non-insulin dependent diabetes or  
 
Type 2 diabetes. In this study, S. cordatum (12.5-50 mg/kg, p.o.) and chlorpropamide (250 
 
mg/kg, p.o.) significantly reduced the blood glucose concentration of fasted normal rats while  
 
0.3 ml (p.o.) of physiological saline did not alter the blood glucose concentration of the fasted  
 
normal rats. Similarly, both the leaf aqueous extract of S. cordatum (12.5-50 mg/kg, p.o.) and  
 
chlorpropamide ( 250 mg/kg, p.o.) significantly reduced the glucose concentration of diabetic  
 
rats treated with streptozotocin. Since chlorpropamide used to treat diabetes, acts by  
 
stimulating insulin secretion from pancreatic bête cells and also promoting peripheral glucose  
 
uptake and utilization (Waller et al., 2005a; Rang et al., 2008), it is probable that S. cordatum,  
 
may be acting in a similar manner. The result obtained in this study is in agreement with the  
 
study of Musabayane et al. (2005) who showed that S. cordatum leaf extract significantly  
 
lowered the plasma glucose and hepatic glycogen levels in STZ-induced diabetic rats. 
 
 
In this study, the phytochemical analysis carried out revealed the presence of alkaloids and  
 
flavonoids amongst other chemical metabolites in S. cordatum. Punitha et al. (2005) in their  
 
study with berberine, an alkaloid, and antidiabetic activity, showed that alkaloids have  
 
antidiabetic activity. Dineshkumar et al. (2010) in their study on the antidiabetic and  
 
hypolipidemic effects of mahanimbin from Murraya koenigii leaves also showed that  
 
alkaloids have antidiabetic activity. Flavonoids have also been shown by the study of Ghada  
 
et al. (2008) which investigated the antidiabetic and antioxidant activities of major flavonoids  
 
ofCynanchum acutum L., to have antidiabetic activity. Furthermore, Hule et al. (2011) in  
 
their study on the evaluation of the antidiabetic effects of Elaeocarpus ganitrus in  
 
experimental animals, showed that alkaloids and flavonoids have antidiabetic activities. It is  
 
probable therefore, that the flavonoids and alkaloids found in S. cordatum may be  
 
contributing to its antidiabetic activity. 
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CHAPTER 6 
 
CONCLUSION 
 
The data obtained in this study indicate that Syzygium cordatum have both antidiarrhoeal and 
 
antidiabetic activities. This project was not set out to investigate the mechanisms of the 
 
antidiarrhoeal and antidiabetic activities of S. cordatum. However, various studies as shown  
 
above, have shown that castor oil-induced diarrhoea may also involve increase in electrolyte  
 
permeability, increased release of prostaglandins and nitric acid mechanism. It is probable  
 
therefore, that the antidiarrhoeal activity of S. cordatum may involve the inhibition of  
 
electrolyte permeability, inhibition of prostaglandin release and inhibition of nitric acid  
 
mechanism. The antidiabetic activity may be due to the plant species stimulating the release  
 
of insulin from the pancreatic beta cells since streptozotocin used to induce diabetes is  
 
known to act by rapidly depleting  pancreatic beta cells and thus, reducing insulin release.  
 
The role of tannins in the antidiarrhoeal activity and alkaloids and flavonoids in the  
 
antidiabetic activity of S. cordatum also needs mentioning. The relatively high LD50 of the  
 
plant species shows that it is non-toxic and /or safe in mice. These data may justify the use of  
 
the plant species by traditional medicine practitioners in the treatment of diarrhoea and  
 
diabetes especially Type 2 or non-insulin dependent diabetes. However, further studies on the  
 
acute toxicity and the mechanisms of the antidiarrhoeal and antidiabetic activities of S.  
 
cordatum need to be carried out to enhance the safety and efficacy of the plant species. 
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